Avaglim (rosiglitazone;glimepiride)
- Region
- 🇪🇺 EU
- Active substance
- rosiglitazone;glimepiride
- Company
- SmithKline Beecham Ltd
- Status
- Withdrawn
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Tue 27 Jun 2006
- Application
- EMEA/H/C/000675
- ATC
- A10BD04
- Official record
- www.ema.europa.eu
Indication
AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.
Regulatory milestones
No milestones recorded in the last year.
Follow Avaglim
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.